keyword
MENU ▼
Read by QxMD icon Read
search

sirolimus

keyword
https://www.readbyqxmd.com/read/29035435/clinical-and-angiographic-outcomes-of-the-first-korean-made-sirolimus-eluting-coronary-stent-with-abluminal-bioresorbable-polymer
#1
Hyoung Mo Yang, Kyoung Woo Seo, Junghan Yoon, Hyo Soo Kim, Kiyuk Chang, Hong Seok Lim, Byoung Joo Choi, So Yeon Choi, Myeong Ho Yoon, Seung Hwan Lee, Sung Gyun Ahn, Young Jin Youn, Jun Won Lee, Bon Kwon Koo, Kyung Woo Park, Han Mo Yang, Jung Kyu Han, Ki Bae Seung, Wook Sung Chung, Pum Joon Kim, Yoon Seok Koh, Hun Jun Park, Seung Jea Tahk
BACKGROUND AND OBJECTIVES: This trial evaluated the safety and efficacy of the Genoss drug-eluting coronary stent. METHODS: This study was a prospective, multicenter, randomized trial with a 1:1 ratio of Genoss drug-eluting stent (DES)™ and Promus Element™. Inclusion criteria were the presence of stable angina, unstable angina, or silent ischemia. Angiographic inclusion criteria were de novo coronary stenotic lesion with diameter stenosis >50%, reference vessel diameter of 2...
September 18, 2017: Korean Circulation Journal
https://www.readbyqxmd.com/read/29027737/an-optical-coherence-tomography-study-of-neointimal-morphology-and-strut-coverage-at-different-time-intervals-from-implantation-of-biodegradable-polymer-coated-sirolimus-eluting-stents
#2
Jacek Legutko, Robert J Gil, Pawel E Buszman, Grzegorz L Kaluza, Gary S Mintz, Tomasz Roleder, Marek Krol, Roman Wojdyla, Tomasz Pawlowski, Michal Brzezinski, Marek Kondys, Bartosz Skwarna, Jacek Jakala, Wojciech Zasada, Lukasz Partyka, Dariusz Dudek
OBJECTIVES: The aim of the study was to capture the evolution of neointima after implantation of a biodegradable polymer-coated, sirolimus-eluting, cobalt-chromium coronary stent system (BP-DES). BACKGROUND: Optical coherence tomography (OCT) suggests that in-stent neointimal morphology influences clinical outcomes after DES implantation. METHODS: Sixty patients treated with single BP-DES implantation were examined by quantitative coronary angiography (QCA) and OCT at 3, 6, and 12-month follow-up...
October 13, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29025834/study-protocol-for-a-randomised-controlled-trial-harmonising-optimal-strategy-for-treatment-of-coronary-artery-stenosis-coronary-intervention-with-next-generation-drug-eluting-stent-platforms-and-abbreviated-dual-antiplatelet-therapy-host-idea-trial
#3
Chi-Hoon Kim, Jung-Kyu Han, Han-Mo Yang, Kyung Woo Park, Hae-Young Lee, Hyun-Jae Kang, Bon-Kwon Koo, Namho Lee, Tae-Joon Cha, Tae-Hyun Yang, Myung-Ho Jeong, Myeong-Ho Yoon, Seung Uk Lee, Seung Jin Lee, Jin Won Kim, Jin-Man Cho, Kyu-Rock Han, Wook Bum Pyun, Hyo-Soo Kim
INTRODUCTION: We have recently seen the introduction of newer generation drug-eluting stents with ultrathin struts that use advanced polymer technologies. However, the efficacy and safety of these newest stents have not yet been fully explored. In addition, there are still controversies over the optimal duration of dual antiplatelet therapy (DAPT) after stent implantation, particularly for ultrathin stents with the newest polymer technologies. METHODS AND ANALYSIS: The HOST-IDEA trial is a randomised, open-label, multicentre, non-inferiority trial and the first study to directly compare two of these ultrathin sirolimus-eluting stents: Orsiro stent with biodegradable polymer, and polymer-free Coroflex ISAR (CX-ISAR) stent...
October 11, 2017: BMJ Open
https://www.readbyqxmd.com/read/29021448/additional-octreotide-therapy-to-sirolimus-achieved-a-decrease-in-sirolimus-refractory-chylous-effusion-complicated-with-lymphangioleiomyomatosis
#4
Masashi Namba, Takeshi Masuda, Takashi Nakamura, Yasushi Horimasu, Shintaro Miyamoto, Taku Nakashima, Hiroshi Iwamoto, Kazunori Fujitaka, Hironobu Hamada, Noboru Hattori
Recently, sirolimus, an inhibitor of mammalian target of rapamycin, was reported to decrease chylous effusion in patients with lymphangioleimyomatosis (LAM). We herein report a case of a 34-year-old woman with LAM who developed refractory chylothorax and chylous ascites during sirolimus therapy. In this case, to reduce chylous effusion, we administered octreotide, which is often used to control postoperative chylous effusion, in addition to the sirolimus therapy. This combination therapy reduced the chylothorax and chylous ascites...
October 11, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29021434/effectiveness-of-bare-metal-stent-implantation-for-the-treatment-of-coronary-artery-aneurysm-a-multimodality-imaging-evaluation
#5
Yasuaki Hada, Hiroyuki Fujii, Masato Shimizu, Noriyoshi Yamawake, Mitsuhiro Nishizaki
Coronary artery aneurysm (CAA) after sirolimus-eluting stent (SES) implantation is one of the most troublesome problems associated with first-generation drug-eluting stents. However, the natural course and standard therapy of CAA has been unknown. A 49-year-old man underwent SES implantation for the left anterior descending artery. Follow-up coronary angiography (CAG) revealed CAA in the SES. We performed bare metal stent (BMS) implantation for treatment of CAA. Ten months after the BMS implantation, the size of the CAA had diminished, and a very thin layer of endothelium on the BMS was observed by optical coherence tomography...
October 11, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28994655/functional-comparison-between-buma-supreme-biodegradable-polymer-sirolimus-eluting-and-durable-polymer-zotarolimus-eluting-coronary-stents-using-quantitative-flow-ratio-pioneer-qfr-substudy
#6
Taku Asano, Yuki Katagiri, Carlos Collet, Erhan Tenekecioglu, Yosuke Miyazaki, Yohei Sotomi, Giovanni Amoroso, Adel Aminian, Salvatore Brugaletta, Mathias Vrolix, Rosana Hernandez-Antolín, Pim van de Harst, Andres Iñiguez, Luc Janssens, Pieter Smits, Joanna J Wykrzykowska, Vasco Gama Ribeiro, Helder Periera, Pedro Canas da Silva, Jan J Piek, Johan H C Reiber, Clemens von Birgelen, Manel Sabaté, Yoshinobu Onuma, Patrick W Serruys
AIMS: Quantitative Flow Ratio (QFR) based on 3-dimensional quantitative coronary angiography (3D-QCA) is a novel method to assess the physiological functionality after treatment with stents. The current study aimed to evaluate the difference in physiological functionality 9 months after implantation of a bioresorbable polymer-based sirolimus-eluting stent with an electrografting base layer (BuMA Supreme: B-SES) versus a durable polymer-based zotarolimus-eluting stent (Resolute: R-ZES)...
October 10, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28993730/molecular-guided-therapy-provides-sustained-clinical-response-in-refractory-choroid-plexus-carcinoma
#7
Albert Cornelius, Jessica Foley, Jeffrey Bond, Abhinav B Nagulapally, Julie Steinbrecher, William P D Hendricks, Maria Rich, Sangeeta Yendrembam, Genevieve Bergendahl, Jeffrey M Trent, Giselle S Sholler
Choroid plexus carcinomas (CPCs) are rare, aggressive pediatric brain tumors with no established curative therapy for relapsed disease, and poor survival rates. TP53 Mutation or dysfunction correlates with poor or no survival outcome in CPCs. Here, we report the case of a 4 month-old female who presented with disseminated CPC. After initial response to tumor resection and adjuvant-chemotherapy, the tumor recurred and metastasized with no response to aggressive relapse therapy suggesting genetic predisposition...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28990343/efficacy-and-safety-of-a-biodegradable-polymer-cobalt-chromium-sirolimus-eluting-stent-excel2-in-treating-de-novo-coronary-artery-disease-a-pooled-analysis-of-the-credit-ii-and-credit-iii-trials-doi-10-1002-ccd-26887
#8
Geng Wang, Heyang Wang, Bo Xu, Yuejin Yang, Zhiming Yang, Hui Li, Zheng Zhang, Haichang Wang, Lixia Yang, Yaling Han
No abstract text is available yet for this article.
October 1, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28985184/sirolimus-precipitating-diabetes-mellitus-in-a-patient-with-congenital-hyperinsulinaemic-hypoglycaemia-due-to-autosomal-dominant-abcc8-mutation
#9
Antonia Dastamani, Maria Güemes, Joanna Walker, Pratik Shah, Khalid Hussain
BACKGROUND: Sirolimus (mTOR inhibitor) is proven to be effective in children with congenital hyperinsulinism (CHI). Studies in animals suggest that sirolimus may have diabetogenic actions. However, its role in precipitating diabetes mellitus (DM) in children with CHI has not been reported. CASE PRESENTATION: A 16-year-old female with CHI due to a dominant ABCC8 gene mutation was switched from diazoxide therapy to sirolimus, due to the hypertrichosis side effect of diazoxide...
October 6, 2017: Journal of Pediatric Endocrinology & Metabolism: JPEM
https://www.readbyqxmd.com/read/28974433/impact-of-immunosuppressive-drugs-on-circulating-tfh-cells-in-kidney-transplant-recipients-a-pilot-study
#10
Ya Mei Li, Yi Li, Yun Ying Shi, Lin Yan, Xiao Juan Wu, Jiang Tao Tang, Yang Juan Bai, Lan Lan Wang
BACKGROUND: T follicular helper cells (Tfh) are recently revealed to be vital in antibody-mediated rejection (AMR) in kidney transplant recipients (KTRs). However, the impact of immunosuppressive drugs on Tfh cells is not fully understood. The purpose of this study was to investigate the variation of Tfh cells phenotypically and functionally in KTRs treated with different immunosuppression regimens. METHODS: We recruited 26 KTRs treated with tacrolimus (TAC) -based regimen, 13 with sirolimus (SRL) -based regimen and 10 healthy controls (HC) in this study...
September 30, 2017: Transplant Immunology
https://www.readbyqxmd.com/read/28972684/the-effects-of-topical-aqueous-sirolimus-on-tear-production-in-normal-dogs-and-dogs-with-refractory-dry-eye
#11
Ronald Spatola, Brad Nadelstein, Andrew Berdoulay, Robert V English
PURPOSE: To evaluate the effect of twice daily aqueous 0.02% sirolimus drops on tear production in normal dogs and dogs with refractory keratoconjunctivitis sicca (KCS). METHODS: Two groups of dogs were studied. Ten normal dogs with no signs of ocular disease were administered topical 0.02% sirolimus ophthalmic solution in right eye, and a vehicle control in the left eye twice daily for 4 weeks. Complete ophthalmic examinations, including Schirmer tear test were performed weekly...
October 3, 2017: Veterinary Ophthalmology
https://www.readbyqxmd.com/read/28970719/autoimmune-hepatitis-standard-treatment-and-systematic-review-of-alternative-treatments
#12
REVIEW
Benedetta Terziroli Beretta-Piccoli, Giorgina Mieli-Vergani, Diego Vergani
Autoimmune hepatitis is a rare chronic inflammatory liver disease, affecting all ages, characterised by elevated transaminase and immunoglobulin G levels, positive autoantibodies, interface hepatitis at liver histology and good response to immunosuppressive treatment. If untreated, it has a poor prognosis. The aim of this review is to summarize the evidence for standard treatment and to provide a systematic review on alternative treatments for adults and children. Standard treatment is based on steroids and azathioprine, and leads to disease remission in 80%-90% of patients...
September 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28966335/randomized-prospective-comparison-of-everolimus-eluting-vs-sirolimus-eluting-stents-in-patients-undergoing-percutaneous-coronary-intervention%C3%A3-3-year-clinical-outcomes-of-the-excellent-randomized-trial
#13
Kyung Woo Park, Tae-Min Rhee, Hyun-Jae Kang, Bon-Kwon Koo, Hyeon-Cheol Gwon, Jung-Han Yoon, Do-Sun Lim, In-Ho Chae, Kyoo-Rok Han, Taehoon Ahn, Myung-Ho Jeong, Dong-Woon Jeon, Yang-Soo Jang, Hyo-Soo Kim
BACKGROUND: Everolimus-eluting stents (EES) have equivalent short-term angiographic and clinical outcomes to sirolimus-eluting stents (SES), but EES may be superior to SES with regard to long-term clinical safety. We report the 3-year clinical outcomes of EES and SES from the prospective EXCELLENT Randomized Trial (NCT00698607).Methods and Results:We randomly assigned 1,443 patients undergoing percutaneous coronary intervention 3:1 to receive EES and SES, respectively. We investigated endpoints including target lesion failure (TLF) and individual clinical outcomes including stent thrombosis (ST) at 3 years...
September 30, 2017: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/28965166/comparative-assessment-of-three-drug-eluting-stents-with-different-platforms-but-with-the-same-biodegradable-polymer-and-the-drug-based-on-quantitative-coronary-angiography-and-optical-coherence-tomography-at-12-month-follow-up
#14
Robert J Gil, Jacek Bil, Jacek Legutko, Tomasz Pawłowski, Katarzyna E Gil, Dariusz Dudek, Ricardo A Costa
The aim of this study was to compare neointima proliferation in three drug-eluting stents (DES) produced by the same company (Balton, Poland) which are covered with a biodegradable polymer and elute sirolimus (concentration: 1.0 and 1.2 µg/mm(2)), but have different stent platforms and strut thickness: stainless steel Prolim(®) (115 µm) and BiOSS LIM(®) (120 µm) and cobalt-chromium Alex(®) (70 µm). We analyzed data of patients with quantitative coronary angiography (QCA) and optical coherence tomography (OCT) at 12 months from BiOSS LIM Registry, Prolim Registry and Alex OCT clinical trial...
September 30, 2017: International Journal of Cardiovascular Imaging
https://www.readbyqxmd.com/read/28964764/the-sabre-trial-sirolimus-angioplasty-balloon-for%C3%A2-coronary-in-stent-restenosis-angiographic-results-and-1-year-clinical-outcomes
#15
Stefan Verheye, Mathias Vrolix, Indulis Kumsars, Andrejs Erglis, Dace Sondore, Pierfrancesco Agostoni, Kristoff Cornelis, Luc Janssens, Michael Maeng, Ton Slagboom, Giovanni Amoroso, Lisette Okkels Jensen, Juan F Granada, Pieter Stella
OBJECTIVES: The aim of this first-in-human study was to assess the safety and effectiveness of the Virtue sirolimus-eluting balloon in a cohort of patients with in-stent restenosis (ISR). BACKGROUND: Angioplasty balloons coated with the cytotoxic drug paclitaxel have been widely used for ISR treatment. The Virtue angioplasty balloon (Caliber Therapeutics, New Hope, Pennsylvania) delivers sirolimus in a nanoencapsulated liquid formulation. This clinical trial is the first to examine a sirolimus-eluting balloon for ISR...
September 19, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28964761/the-debut-of-sirolimus-eluting-balloons-the-final-nail-in-the-coffin-for-in-stent-restenosis
#16
EDITORIAL
Raffaele Piccolo
No abstract text is available yet for this article.
September 19, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28951394/impact-of-stent-size-selection-on-acute-and-long-term-outcomes-after-drug-eluting-stent-implantation-in-de-novo-coronary-lesions
#17
Hideki Kitahara, Kozo Okada, Takumi Kimura, Paul G Yock, Alexandra J Lansky, Jeffrey J Popma, Alan C Yeung, Peter J Fitzgerald, Yasuhiro Honda
BACKGROUND: Although significant undersizing often results in incomplete stent apposition or underexpansion, the possible impact of oversized stent implantation on arterial wall injury has not been systematically investigated with drug-eluting stents. The aim of this study was to investigate the impact of stent oversizing on acute and long-term outcomes after drug-eluting stents implantation in de novo coronary lesions. METHODS AND RESULTS: Serial (baseline and 6-12 months) coronary angiography and intravascular ultrasound were performed in 2931 lesions treated with drug-eluting stents (355 sirolimus, 846 paclitaxel, 1387 zotarolimus, and 343 everolimus)...
October 2017: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28944613/propensity-score-matched-all-comers-population-treated-with-ultra-thin-strut-bare-metal-and-sirolimus-probucol-coated-drug-eluting-stents-of-identical-stent-architecture
#18
Florian Krackhardt, Mohd Ali Rosli, Matthias Leschke, André Schneider, Christian Sperling, Tay Mok Heang, Maxime Pons, Pedro Jerónimo Sousa, Behrouz Kherad, Matthias Waliszewski
OBJECTIVE: The objective of this study was to compare the safety and efficacy of a polymer-free sirolimus coated, ultrathin strut drug eluting stent (PF-SES) to its uncoated bare-metal stent (BMS) platform of identical stent architecture. BACKGROUND: Recently published randomized trials comparing BMS to DES with a focus on shortened dual-antiplatelet therapy reported incidences of stent thrombosis (ST) and bleeding complications (LEADERS FREE) in favor of drug eluting stents (DES)...
September 25, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28941319/donor-derived-kaposi-s-sarcoma-in-a-liver-kidney-transplant-recipient
#19
S C Dollard, D Douglas, S V Basavaraju, D S Schmid, M Kuehnert, B Aqel
Human herpes virus 8 (HHV-8), also known as Kaposi's sarcoma associated herpesvirus (KSHV), is an oncogenic virus that can cause Kaposi's sarcoma (KS). KS can develop following organ transplantation through reactivation of the recipient's latent HHV-8 infection, or less commonly through donor-derived infection which has higher risk for severe illness and mortality. We describe a case of probable donor-derived KS in the recipient of a liver-kidney transplant. The donor had multiple risk factors for HHV-8 infection...
September 23, 2017: American Journal of Transplantation
https://www.readbyqxmd.com/read/28935075/6-month-clinical-and-angiographic-outcomes-of-a-novel-radiopaque-sirolimus-eluting-bioresorbable-vascular-scaffold-the-fantom-ii-study
#20
Alexandre Abizaid, Didier Carrié, Norbert Frey, Matthias Lutz, Joachim Weber-Albers, Darius Dudek, Bernard Chevalier, Shu-Chuan Weng, Ricardo A Costa, Jeffrey Anderson, Gregg W Stone
OBJECTIVES: The purpose of this study was to evaluate the outcomes of the novel Fantom coronary bioresorbable scaffold at 6 months. BACKGROUND: The Fantom sirolimus-eluting bioresorbable scaffold incorporates a unique proprietary iodinated, polycarbonate copolymer of tyrosine analogs that is radiopaque, with thin struts (125 μm) that facilitate device delivery and precise target lesion treatment. METHODS: The 6-month outcomes and performance of the Fantom scaffold were evaluated in 117 patients with single de novo native coronary artery lesions of length ≤20 mm and reference vessel diameter 2...
September 25, 2017: JACC. Cardiovascular Interventions
keyword
keyword
4707
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"